Navigation Links
Poniard Pharmaceuticals Secures $20 Million Committed Equity Financing Facility
Date:2/23/2010

ts based on a number of factors, including risks and uncertainties inherent in the Company's business, including, but not limited to, the results and timing of the Company's discussions with the FDA; the potential safety, efficacy and commercial viability of picoplatin; the risk that the Company's additional analyses of data from clinical trials of picoplatin may produce negative or inconclusive results, or may be inconsistent with previously announced results or previously conducted trials; the Company's anticipated operating losses, need for future capital and ability to obtain future funding; the Company's ability to retain key personnel and enter into strategic partnerships on favorable terms, or at all; competition from third parties; the Company's ability to preserve and protect its intellectual property rights; the Company's dependence on third-party manufacturers, suppliers and other contractors; changes in technology, government regulation and general market conditions; the receipt and timing of any FDA and other required regulatory approvals, if any; and the risks and uncertainties described in the Company's current and periodic reports filed with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K for the year ended December 31, 2008, and its Quarterly Report on Form 10-Q for the period ended September 30, 2009. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to update any forward-looking statement to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.

SOU
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Pharmaceuticals to Present at 12th Annual BIO CEO and Investor Conference
2. Poniard Pharmaceuticals Announces Management Changes and Reduction in Force
3. Poniard Pharmaceuticals Announces Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer Meets Primary Endpoint and Study Objectives
4. Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results
5. Poniard Pharmaceuticals Announces Positive Cardiac Safety Data From Picoplatin Phase 1 Trial Supporting NDA Filing
6. Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
7. Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update
8. Poniard Pharmaceuticals to Present New Data from Phase 2 Clinical Trials of Picoplatin in Multiple Tumor Types at the 45th Annual Meeting of the American Society of Clinical Oncology
9. Poniard Completes Patient Enrollment Target in Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer
10. Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update
11. Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  Zafgen, Inc., a leading biopharmaceutical company dedicated to ... today announced initial results from its Phase 2a ... aminopeptidase 2 (MetAP2), in patients with Prader-Willi syndrome ... results showed improvements in body weight, hunger-related behaviors, ...
(Date:1/14/2014)... , Jan. 14, 2014 The Brandeis Medical Center, led by ... a premier and affordable laser tattoo removal experience with the ... focus is in providing high quality cosmetic services with cutting edge ... " Southern California has seen a dramatic ...
(Date:1/14/2014)... CLEVELAND , Jan. 14, 2014 NineSigma ... will hold its Innovation Leadership Summit , May ... in Cleveland Ohio . ... innovators and organizations committed to breakthrough achievements through open ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4
... 2011  Thoratec (NASDAQ: THOR), a world leader in device-based ... failing hearts, said today it will be participating in ... Tuesday, December 13. Taylor C. Harris, Senior ... an update on the company, beginning at 10:15 a.m., ...
...  VolitionRX Limited (VNRX.OB), a life sciences company focused on ... it will issue US$1,110,000 worth of shares of its ... issuance is the final requirement of the Share Purchase ... June 2011) between ValiRx and Singapore Volition Pte Limited, ...
Cached Medicine Technology:VolitionRX Limited Issues 525,000 Shares to ValiRx; Final Requirement of Share Purchase Agreement 2
(Date:4/18/2014)... Johns Hopkins University School of Medicine researchers have been ... for diabetes, Novo Nordisk announced this month. Of the ... and Obesity Biologics Science Forum Program, only four projects ... Hopkins researchers. They are Jonathan Powell, M.D., Ph.D.; G. ... , Jonathan Powell, a professor of oncology, will use ...
(Date:4/18/2014)... WA April 18, 2014) Benaroya Research Institute ... research how blocking a particular molecule in metastatic breast ... the number of lung metastases. BRI scientists have found ... can shrink tumors by 60 - 80 percent and ... the lung. The $1.8 million five-year grant comes from ...
(Date:4/18/2014)... San Diego, Calif. (April 18, 2014) ― A new ... analyzing weekly patterns in health-related Google searches reveals ... public health strategies. , Investigators from San ... University, and the Monday Campaigns, analyzed "healthy" Google searches ... health-related, e.g., "healthy diet") originating in the U.S. from ...
(Date:4/18/2014)... could lead to potential new treatments for breaking the ... , Fibrosis, or scarring, is a hallmark of the ... can lead to serious organ damage and, in some ... centers on findings made by Swati Bhattacharyya, PhD, research ... a specific protein plays in promoting fibrosis. , ...
(Date:4/17/2014)... in non-cancerous prostate tissue may have nearly twice the ... no inflammation, according to results of a new study ... Center. , The link between persistent inflammation and cancer ... cancer those with a Gleason score between 7 ... aggressive and rapidly growing prostate cancers. , "What we,ve ...
Breaking Medicine News(10 mins):Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:New research shows people are thinking about their health early in the week 2Health News:New clues on tissue scarring in scleroderma 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3
... Oct. 15 One Heartland will host "S,more to Love", a ... Open House Lofts, NYC to benefit Birch Family Camp. , Celebrating ... (over 200 family members) from the 5 boroughs of NYC, along ... building at a camp facility located in the Hudson Valley. ...
... 15 The Longaberger Company is teaming up with the ... against breast cancer. As part of the "Crucial Catch" campaign ... players - in partnership with the American Cancer Society - ... feature players, coaches and referees wearing pink game apparel to ...
... TALLAHASSEE, Fla. -- A Florida State University College of Medicine ... Institutes of Health (NIH) totaling $2.4 million to continue her ... months. Amy Wetherby is director of the Autism Institute ... WORDS Project has screened children to identify early red flags ...
... to curtail secondhand smoke, experts say , , THURSDAY, Oct. ... really do work at reducing heart attacks from secondhand smoke, ... the risk of heart attack by up to 47 ... according to a report released Thursday by the U.S. Institute ...
... Oct. 15 Astrup Drug Inc. has announced ... (ECRS) point-of-sale retail automation suite in their 11 ... selected by Astrup Drug to seamlessly automate their ... convenience/fuel integration, warehousing, front-end inventory control, and centralized ...
... for Presentation Also Nominated for Prestigious Prize , ... nine abstracts based on research by a total of 15 ... doctors, researchers and psychological social workers will be featured this ... meeting in Atlanta. , (Logo: http://www.newscom.com/cgi-bin/prnh/20090203/DC66439LOGO ...
Cached Medicine News:Health News:One Heartland Hosting: S'more to Love Cocktail Fundraiser 2Health News:FSU researcher wins $2.4M in grants to pursue early detection of autism 2Health News:FSU researcher wins $2.4M in grants to pursue early detection of autism 3Health News:Smoking Bans Reduce Heart Attacks: Study 2Health News:Smoking Bans Reduce Heart Attacks: Study 3Health News:Astrup Drug Implements ECRS Retail Solution Suite to Address Diverse Business Requirements 2Health News:Shady Grove Fertility Center Research to Be Showcased at Premier Annual Medical Conference on Reproductive Medicine 2Health News:Shady Grove Fertility Center Research to Be Showcased at Premier Annual Medical Conference on Reproductive Medicine 3Health News:Shady Grove Fertility Center Research to Be Showcased at Premier Annual Medical Conference on Reproductive Medicine 4
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: